Reduction in Invasive Pneumococcal Disease Following Implementation of the Conjugate Vaccine in the Oxfordshire Region, England.
Summary of "Reduction in Invasive Pneumococcal Disease Following Implementation of the Conjugate Vaccine in the Oxfordshire Region, England."
Pneumococcal conjugate vaccine to 7 capsular types has been highly effective in the US since its introduction in 2000. The same vaccine was adopted by the UK in 2006. Ongoing surveillance since 1995 of invasive pneumococcal disease in Oxfordshire, UK, allowed assessment of the impact of vaccine intervention. The vaccine significantly reduced invasive pneumococcal disease among the target group, children less than 2 years; incidence rate ratio (IRR)=0.62 [95%CI 0.43-0.90] (p=0.008) comparing the 3 years pre- and post-implementation with a residual incidence of 22.4/100,000 children. The reduction was even greater when comparing 11 years pre with the 3 years post implementation of vaccine; IRR=0.53 [0.39- 0.70] p<0.0001. There was a marked direct effect of the vaccine evidenced by substantial reductions in the 7 serotypes contained in the vaccine. There was also a clear reduction in invasive pneumococcal disease for those serotypes contained in the vaccine among those older than 2 years when comparing both the 3 and 11 year pre PCV7 time periods with IRR=0.57 [0.47-0.69] p<0.0001 and IRR=0.50 [0.43-0.58] p<0.0001 respectively, indicating a strong herd effect. There was a significant, though moderate, rise in the serotypes not contained in the vaccine, with clear evidence for replacement in some serotypes.
1 University of Oxford;
This article was published in the following journal.
Name: Journal of medical microbiology
- PubMed Source: http://www.ncbi.nlm.nih.gov/pubmed/20864548
- DOI: http://dx.doi.org/10.1099/jmm.0.023135-0
Background. The 7-valent pneumococcal conjugate (PCV7) vaccine's impact on invasive pneumococcal disease (IPD) is well described, but few reports exist on the additional impact of the 13-valent vacc...
Racial differences have been well described for invasive pneumococcal disease (IPD), but little information exists on how race interacts with community socioeconomic factors.
Invasive pneumococcal disease (IPD) continues to occur at high rates among Australian Aboriginal people. The seven-valent pneumococcal conjugate vaccine (7vPCV) was given in a 2-4-6-month schedule fro...
The 7-valent pneumococcal protein conjugate vaccine (PCV7) has been shown to be highly efficacious against invasive pneumococcal diseases and effective against pneumonia and in reducing otitis media....
The primary purpose of this study is to characterize the immune response to a single dose of 13-valent pneumococcal conjugate vaccine (13vPnC) in children previously vaccinated with a prim...
Two( 2) or three (3) instead of four vaccinations before the age of 6 months with pneumococcal conjugate vaccine are presumed to protect children against invasive pneumococcal disease like...
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vPnC), relative to a 7-valent pneumococcal conjugate va...
To assess whether HIV-infected infants who receive a heptavalent pneumococcal conjugate vaccine have more local reactions at the site of injection and systemic reactions than placebo subje...
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomita...
Medical and Biotech [MESH] Definitions
A combined vaccine used to prevent infection with diphtheria and tetanus toxoid. This is used in place of DTP vaccine (DIPHTHERIA-TETANUS-PERTUSSIS VACCINE) when PERTUSSIS VACCINE is contraindicated.
A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)
A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.
An attenuated vaccine used to prevent and/or treat HERPES ZOSTER, a disease caused by HUMAN HERPESVIRUS 3.
A bacterial vaccine for the prevention of brucellosis in man and animal. Brucella abortus vaccine is used for the immunization of cattle, sheep, and goats.